Related to Novartis Plans Filing for Myelofibrosis Candidate in Light of Positive Phase III Data

• Novartis to Evaluate NasVax Adjuvant Technology
  
• FDA Sanctions Novartis’ Vaccine for Meningococcal Disease in Adolescents and Adults
  
• EC Clears Novartis’ Quadrivalent Meningitis Vaccine
  
• Novartis Pulls MAA for HCV Therapy Developed with Human Genome Sciences
  
• Novartis to Pay $45M Up Front in Cancer Collaboration with Array BioPharma
  
• FDA Clears Novartis’ Zortress for Preventing Organ Rejection in Kidney Transplant Patients
  
• Vectura Bags $7.5M as Novartis Starts Phase III Development of COPD Therapy
  
• Late-Stage Data Shows that Novartis’ Afinitor Extends PFS in Advanced Pancreatic NET
  
• FDA Green-Lights Novartis’ Tasigna as First-Line Therapy for Newly Diagnosed Ph+ CML
  
• FDA Green-Lights Genentech’s Lucentis for Macular Edema following Retinal Vein Occlusion
  
• Phase III Data Shows Novartis’ Afinitor More Than Doubles PFS in Pancreatic NET Patients
  
• Interim Analysis of Novartis’ Osteoarthritis Therapy Suggests Lack of Efficacy Benefit
  
• GenVec and Novartis Cement Hearing Loss Partnership with Manufacturing Deal
  
• Novartis Shells Out $10M for Option to Quark’s Phase II-Stage Synthetic siRNA
  
• FDA Okays Novartis’ Hypertension Combination Therapy
  
• Novartis and Collaborators Discover Candidate for Drug-Resistant Malaria
  
• Russian Authorities Become First to Sanction Novartis’ Oral MS Therapy
  
• Novartis’ Onbrez Breezhaler Trumps Salmeterol in Phase III COPD Trial
  
• Novartis Gets FDA OK for MS Therapy and Makes Headway against Cushing Disease
  
• Warner Chilcott Acquires Sole U.S. Rights to Novartis’ Marketed Overactive Bladder Drug for $400M